SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : The Justa & Lars Honors Bob Brinker Investment Club
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: marc ultra who wrote (4541)4/19/1999 2:38:00 PM
From: marc ultra  Read Replies (2) of 15132
 
Just picked up some MRK at 74 1/2. I believe they're going before FDA advisory committee tomorrow with Vioxx which if approved should be a blockbuster as the latest "cox-2 inhibitor" which are drugs like Motrin but shouldn't cause much danger of stomach irritation and ulcers. A key will be whether it is recommended for labeling for both pain relief as well as arthritis, if just arthritis could be some selling.Monsanto's Celebrex is the first one of these Cox-2 inhibitors to be approved and is selling very strong though has only received labelling for arthritis. These drugs should have a multibillions market but plenty of competition will come on board in the next few years and there's an issue of whether HMO's will want to pay the higher prices over the old NSAID's(nonsteroidal anti-inflammatory drugs). Anyway I felt they beat the price on MRK down enough that I'll take the shot

Marc
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News